Table 3.
Factors associated with timing of chemotherapy by menopausal status
| Premenopausal | Postmenopausal | |||||
|---|---|---|---|---|---|---|
| Adjuvant chemotherapy N = 67 (%) |
NAC N = 33 (%) |
p value | Adjuvant chemotherapy N = 82 (%) |
NAC N = 44 (%) |
p value | |
| Mean age ± SD | 47.2 ± 4.7 | 44.9 ± 5.6 | 0.029 | 60.9 ± 8.6 | 57.2 ± 8.3 | 0.020 |
| BMI | ||||||
| 18.5–25 | 36 (69.2) | 16 (30.8) | 0.453 | 34 (61.8) | 21 (38.2) | 0.063 |
| 25–30 | 16 (57.1) | 12 (42.9) | 18 (54.6) | 15 (45.5) | ||
| ≥ 30 | 11 (73.3) | 4 (26.7) | 26 (81.3) | 6 (18.8) | ||
| Stage | ||||||
| I | 10 (58.8) | 7 (41.2) | 0.536 | 16 (72.7) | 6 (27.3) | 0.312 |
| II | 36 (72.0) | 14 (28.0) | 35 (58.3) | 25 (41.7) | ||
| III | 21 (63.6) | 12 (36.4) | 31 (70.5) | 13 (29.6) | ||
| Tumor size (mean ± SD, cm) | 4 ± 3.1 | 4.8 ± 4.2 | 0.035 | 3.81 ± 2.6 | 5.18 ± 3.6 | 0.016 |
| Number of positive lymph nodes (mean ± SD) | 2.9 ± 5.3 | 3.7 ± 5.4 | 0.463 | 3.68 ± 7.3 | 2 ± 3.3 | 0.150 |
| Tumor multifocality | 36 (81.8) | 8 (18.8) | 0.004 | 31 (68.9) | 14 (31.1) | 0.529 |
| Receptor Subtype | ||||||
| ER+ PR+ HER-2− | 61 (67.0) | 30 (32.9) | 0.481 | 65 (65.66) | 34 (34.34) | 0.876 |
| ER+ PR− HER-2− | 2(50.0) | 2 (50.0) | 16 (64.00) | 9 (36.00) | ||
| Grade | ||||||
| 1 | 12 (48.0) | 13 (52.0) | 0.059 | 18 (60.0) | 12 (40.0) | 0.351 |
| 2 | 47 (73.4) | 17 (26.6) | 53 (65.4) | 28 (34.6) | ||
| 3 | 4 (80.0) | 1 (20.0) | 10 (83.3) | 2 (16.7) | ||
| Ki67 (mean ± SD, percentage) | 12 ± 9.9 | 23.4 ± 4.9 | 0.033 | 13.7 ± 0.8 | 18 ± 10.9 | 0.154 |
| LVI | 5 (55.6) | 4 (44.4) | 0.427 | 13 (68.4) | 6 (31.6) | 0.740 |
| Pleomorphic | 10 (76.9) | 3 (23.1) | 0.415 | 11 (73.3) | 4 (26.7) | 0.475 |
SD Standard deviation, BMI Body mass index, ER Estrogen receptor, PR Progesterone receptor, HER-2 Human epidermal growth factor receptor-2, LVI Lymphovascular invasion